Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Spirogen Ltd.

http://www.spirogen.com/

Latest From Spirogen Ltd.

Silicon Valley Bank Advisor Predicts 2022 Will Be Year For Healthtech, Massive Consolidation

SVB health care advisor Jonathan Norris anticipates more consolidation in devices ahead with many mid-cap public companies looking to acquire innovative technologies to grow, and pushing the “big guys to have to figure out how to move faster.”

Financing M & A

Digital Health Roundup, August/September 2021: Record Digital Health Funding Q1-3 Of $21.3Bn, AAOS Highlights, Regulatory Updates

In this roundup of developments in digital health, we highlight the key news and announcements from August and September.

Digital Health Artificial Intelligence

Finance Watch: Lightstone Ventures Closes $375m Fund To Back Early Stage Biotechs

Private Company Edition: Recent biopharma venture capital financings add up to $1.7bn, including a $135m crossover round for HilleVax after spinning out of Takeda in July to advance a norovirus vaccine, Skyhawk’s $133m in fresh funding and Obsidian’s $115m series B round.

Financing Innovation

ADC’s Phase II Data May Position ‘Lonca’ To Compete With Roche’s Polivy

The antibody-drug conjugate yields a 48% overall and 24% complete response rate in a pivotal Phase II DLBCL study. The Swiss biotech hopes to compete with Polivy and is studying combo therapy with Imbruvica.

Clinical Trials Drug Approval Standards
See All

Company Information

UsernamePublicRestriction

Register